Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

Blood Cancer Journal

Volumn 7, Issue 6, 2017, Pages

  Dimopoulos, M A ^a   Roussou, M ^a   Gavriatopoulou, M ^a   Fotiou, D ^a   Ziogas, D C ^a   Migkou, M ^a   Panagiotidis, I ^a   Eleutherakis Papaiakovou, E ^a   Kanellias, N ^a   Psimenou, E ^a   Marinaki, S ^b   Bacharaki, D ^c   Mparmparoussi, D ^d   Matsouka, C ^d   Giannouli, S ^a   Terpos, E ^a   Kastritis, E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CLINICAL TRIAL; CONVALESCENCE; DISEASE FREE SURVIVAL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECOVERY OF FUNCTION; RENAL DIALYSIS; SURVIVAL RATE;

EID: 85048374598     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2017.49     Document Type: Letter

References (15)

1. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195–200.
2. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34: 1544–1557.
3. Fotiou D, Dimopoulos MA, Kastritis E. Managing renal complications in multiple myeloma. Expert Rev Hematol 2016; 9: 839–850.
4. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.
5. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.
6. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.
7. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.
8. Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P et al. Evolution in the treatment of multiple myeloma and impact on dialysis inde-pendence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016; 6: e409.
9. Cook M, Hutchison C, Fifer L, Gillmore J, Heyne N, Weisel K et al. High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephro-pathy: results of European trial of Free Light Chain removal extended haemo-dialysis in cast nephropathy (EULITE). EHA 2016; Abstract P270.
10. Bridoux F, Pegourie B, Augeul-Meunier K, Royer B, Joly B, Lamy T et al. Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Inter-groupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). Blood 2016; 128: 978–978.
11. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
12. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.
13. Sarkozi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327: 645–656.
14. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863–2869.
15. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E et al. Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Hae-matologica 2016; 102: 593–599.